



# SHUKRA

PHARMACEUTICALS LTD.

28<sup>th</sup> January, 2026

To,  
The General Manager-Listing  
Corporate Relationship  
Department The BSE Limited  
Ground Floor, PJ Towers,  
Dalal Street, Mumbai-  
400001

Scrip Code: 524632

Dear Sir/Madam,

**Sub: Outcome of the meeting of the Board of Directors held on Wednesday, January 28, 2026**  
**Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015.**

With reference and in continuation to our announcement dated October 3, 2025, and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and, we wish to inform you that in terms of special Resolution passed by the Members of the Company at their Extra-ordinary General meeting held on , November 01, 2025 and in accordance with the In-principal Approval, granted by the BSE Limited on January 9 2026, the Meeting of Committee of Directors ("Board") of the Company held today i.e. Wednesday, January 28, 2026 has approved the following:

1. The allotment of 46,43,000 (Forty six Lakhs forty three thousand) Convertible Equity Warrants on Preferential Basis to the allottee under promoter category at an issue price of ₹ 34/- per warrant on preferential basis in accordance with the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 ("SEBI ICDR Regulations") to the below mentioned allottee:

Sr. No.	Name of Proposed allottees	Total Warrants	Category	Issue Price	No. of securities to be allotted	Amount (In Rs.)
1	Anar Jayeshbhai Patel	5,00,000	Promoter-Individual	34	5,00,000	42,50,000
2	Dakshesh Rameshchandra Shah	5,00,000	Promoter-Individual	34	5,00,000	42,50,000
3	Anar Project Private Limited	12,35,000	Promoter, Bodies Corporate	34	12,35,000	1,04,97,500

**CIN : L24231GJ1993PLC019079**





# SHUKRA

PHARMACEUTICALS LTD.

4	Parshva Texchem India Private Limited	12,35,000	Promoter, Bodies Corporate	34	12,35,000	1,04,97,500
5	Navkar Surgical Gujarat Limited	11,73,000	Promoter, Bodies Corporate	34	11,73,000	99,70,500
TOTAL					46,43,000	3,94,65,500

Further, we would like to confirm that the Company has received from the Allottee mentioned above, Twenty-Five Percent of consideration amount aggregating to ₹3,94,65,500 (Rupees Three Crore Ninety-Four Lakhs Sixty-Five Thousand Five Hundred Only) as required under the SEBI ICDR Regulations.

Since, the Company has allotted the warrants, presently there is no change in the paid-up share capital of the Company.

Each warrant, so allotted, is convertible into one fully paid-up equity share of the Company having face value of ₹ 1/ (Rupee one only) each in accordance with the provisions of SEBI ICDR Regulations, on payment of the balance consideration of ₹ 34/- per warrant ("Warrant Exercise Price"), aggregating to ₹ 11,83,96,500 (Rupees Eleven Crore Eighty-Three Ninety-Six Five Hundred Only) being Seventy-Five Percent of the aggregate consideration from the Allottees mentioned above pursuant to exercise of conversion option against each such warrant, within Eighteen months from the date of allotment of the warrants.

The Board Meeting commenced at 7.10 p.m. and concluded at 7.50 p.m.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

**For Shukra Pharmaceuticals Limited**

**SARJEEVAN**  
**SINGH**  
**Sarjeevan**  
**Singh**  
**Director**  
**DIN:08258683**



Encl.: As Above

**CIN : L24231GJ1993PLC019079**





# SHUKRA

PHARMACEUTICALS LTD.

## Annexure- A

SN	Particulars	Details
1	Types of Securities proposed to be issued	Convertible equity warrants carrying a right to subscribe 1 (one) Equity Share per warrant.
2	Types of Issuances	Preferential allotment on a private placement basis in accordance with the provisions of the Companies Act, 2013 and the rules made thereunder and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("ICDR Regulations") and other applicable laws.
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (Approximately)	<p>46,43,000 (Forty six Lakh forty three thousand) Convertible Equity Warrants (hereinafter referred to as "Warrants") on preferential basis ("Preferential Offer") to the promoter category as mentioned below ("Warrant Holder"/" Proposed Allottee") for cash consideration at a price of Rs.34/-, aggregating upto Rs.,15,78,62,000/- (Rupees Fifteen Crore seventy eight Lakhs sixty two thousand Only).</p> <p>The price of the warrants has been determined in accordance with the ICDR Regulations. The preferential issue will be undertaken for cash consideration.</p> <p>An amount equivalent to 25% of the Warrant Issue Price shall be payable at the time of subscription and allotment of each Warrant and the balance 75% shall be payable by the Warrant holder(s) on the exercise of Warrant(s).</p> <p>The price of the warrants and the number of Equity Shares to be allotted on conversion of warrants shall be subject to appropriate adjustments as permitted under applicable laws.</p>
4	Name of the Investors	As per Schedule -I
5	Post allotment of securities- outcome of the subscription	<p>The equity shares are proposed to be allotted to Promoter. Details of the shareholding of Investors in the Company, prior to and after the proposed Preferential Issue, are as under:</p> <p><i>As per Schedule - I</i></p>
6	Issue Price	Rs.34/- (Thirty four Only) per warrant
7	Number of Investor	5

**CIN : L24231GJ1993PLC019079**



# SHUKRA

PHARMACEUTICALS LTD.

8	In case of convertibles — intimation on conversion of securities or on lapse of the tenure of the instrument;	<p>The tenure of the warrants shall not exceed 18 (eighteen) months from the date of allotment. Each warrant shall carry a right to subscribe 1 (one) Equity Share per warrant, which may be exercised in one or more tranches during the period commencing from the date of allotment of warrants until the expiry of 18 (eighteen) months from the date of allotment of the warrants.</p> <p>In the event that, a warrant holder does not exercise the warrants within a period of 18 (Eighteen) months from the date of allotment of such warrants, the unexercised warrants shall lapse and the amount paid by the warrant holders on such Warrants shall stand forfeited by the Company.</p>
9	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not Applicable

**CIN : L24231GJ1993PLC019079**





# SHUKRA

PHARMACEUTICALS LTD.

## Schedule - I

Sr. No.	Name of Shareholder	Pre issue shareholding		Number of Warrants proposed to be issued	Post issue shareholding	
		No. of equity shares held	Percentage		No. of shares Post capital	Percentage of total holding (post diluted)
1	Anar Jayeshbhai Patel	43,60,000	1.00	5,00,000	48,60,000	1.10
2	Dakshesh Rameshchandra Shah	43,60,000	1.00	5,00,000	48,60,000	1.10
3	Anar Project Private Limited	8,22,40,000	18.78	12,35,000	8,34,75,000	18.86
4	Parshva Texchem India Private Limited	7,51,75,600	17.17	12,35,000	7,64,10,600	17.27
5	Navkar Surgical Gujarat Limited	5,16,00,000	11.78	11,73,000	5,27,73,000	11.93
<b>Total</b>		<b>21,77,35,600</b>	<b>49.73</b>	<b>46,43,000</b>	<b>22,23,78,600</b>	<b>50.26</b>

**CIN : L24231GJ1993PLC019079**